Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) investors concerning the Company's possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. ('Hims') and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.'
On this news, Novo Nordisk's stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Novo Nordisk should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments' Substack by Kontra. In this article, we will summarize the bull's thesis on NVO. Novo Nordisk A/S's share was trading at $70.73 as of June 24th. NVO's trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance. A picture of a pharma technician preparing an IV injection of a biopharmaceutical product. Novo Nordisk continues to solidify its leadership in obesity treatment with groundbreaking clinical results and strategic clarity, reinforcing its position as a cornerstone healthcare investment. At the 2025 ADA Scientific Sessions, the company unveiled exceptional data from the REDEFINE 1 trial of its new combination therapy, CagriSema, which achieved a mean weight loss of 22.7% at 68 weeks. Over 60% of patients lost more than 20% of their body weight, with 23% exceeding a 30% reduction—figures that set a new benchmark in obesity care. CagriSema's strong efficacy is coupled with a favorable safety profile, with only 6% of participants discontinuing treatment due to mostly mild gastrointestinal issues. Novo's innovation pipeline also features amycretin, a dual GLP-1 and amylin receptor agonist, showing promising early-stage data for sustained weight loss and further diversifying its leadership in metabolic health. Financially, Novo Nordisk remains highly attractive, with revenues expected to grow from DKK 330 billion in 2025 to DKK 520 billion by 2029, alongside EBIT margins projected around 50%. Valuation metrics support the bullish case: its forward P/E is forecast to decline from 17x in 2025 to under 10x by 2029, and EV/EBITDA from 12.6x to 6.6x. Dividend yields are set to increase steadily, and free cash flow is projected to reach DKK 174 billion by 2029. Novo Nordisk's disciplined capital allocation, strong innovation, and regulatory integrity highlight its potential for long-term outperformance. The company remains a premier name in global healthcare, offering both resilience and upside for investors seeking quality growth. Previously, we covered a on Novo Nordisk A/S by Kontra Investments in May 2025, which highlighted its GLP-1 market dominance, strong Q1 results, and resilience against U.S. headwinds. The company's stock price has appreciated by approximately 4.4% since our coverage. The thesis still stands as Novo's pipeline and financial strength continue to support long-term growth. Kontra shares an identical view but emphasizes CagriSema's clinical data. Novo Nordisk A/S is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 60 hedge fund portfolios held NVO at the end of the first quarter, which was 64 in the previous quarter. While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Yahoo
an hour ago
- Yahoo
AngloGold Ashanti Sells Brazilian Mine for $76 Million to Aura Minerals
AngloGold Ashanti (NYSE:AU) is one of the best-performing NYSE stocks to buy now. Earlier on June 3, 2025, AngloGold Ashanti reached an agreement to sell its interest in the Mineração Serra Grande mine in Goiás (Brazil) to Aura Minerals. The deal is valued at $76 million in cash, with additional deferred consideration payments consisting of a 3% net smelter return on the mine's mineral resources. The transaction is expected to finalize in Q3 2025, pending regulatory approvals from Brazilian authorities, the completion of certain pre-closing obligations, and no material adverse events. The Mineração Serra Grande mine is located near the city of Crixás and is a gold mine that has been in operation since 1987. It comprises 3 mechanized underground mines and an open pit, supported by a metallurgical plant with an annual capacity of 1.5 million tonnes. A group of miners in hard hats and safety gear descending into a deep coal mine. Despite recent efforts to stabilize operations, including the near-completion of decommissioning at its legacy tailings storage facility, the mine remains one of AngloGold Ashanti's higher-cost and smallest operations in terms of production. In 2024, Mineração Serra Grande produced 80,000 ounces of gold, a slight decrease from 86,000 ounces in 2023. As part of the sale agreement, certain subsidiaries currently under the Mineração Serra Grande operations that hold non-operational assets will be spun off and retained by AngloGold Ashanti. AngloGold Ashanti (NYSE:AU) is a gold mining company in Africa, Australia, and the Americas. It primarily explores for gold, as well as by-products, such as silver and sulphuric acid. While we acknowledge the potential of AU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Business Wire
an hour ago
- Business Wire
Asana Names Dan Rogers as Chief Executive Officer
SAN FRANCISCO--(BUSINESS WIRE)-- Asana, Inc. (NYSE: ASAN) (LTSE: ASAN), a leading enterprise work management platform for human and AI coordination, announced today that Dan Rogers will assume the role of Chief Executive Officer, effective July 21, 2025. A proven executive with extensive experience leading high-growth technology companies, Rogers will succeed Dustin Moskovitz, Asana's Co-Founder and current CEO and Chair. As announced in March, Moskovitz will transition to the role of Chair, where he will contribute to product vision, strategic guidance and supporting Asana's artificial intelligence (AI) initiatives. Rogers joins Asana from LaunchDarkly, where he has served as CEO since 2023. During his tenure, he scaled the business while driving innovation and operational excellence. Rogers has helped some of the most influential companies in the cloud ecosystem to scale and grow their businesses. Prior to LaunchDarkly, Rogers was President of Rubrik, a cloud data management and data security company, and earlier in his career he served as Chief Marketing Officer at ServiceNow. With a track record of leading growth in transformative enterprise SaaS businesses, Rogers is well-positioned to guide Asana in its next phase of profitable growth. "I'm honored to lead Asana during this period of extraordinary transformation and build on the incredible foundation Dustin and the team have created," said Rogers. "Asana is a leading platform where humans and AI coordinate work effortlessly, to unlock enterprise productivity. I look forward to partnering with the talented team at Asana to pursue the next chapter of growth and deliver even greater value to our customers and stakeholders." "This moment represents an unprecedented opportunity for AI to evolve the way people work, and Dan is the leader with the experience, vision, and expertise needed to guide Asana into its next chapter," said Moskovitz. "As I step away from day-to-day operations, I remain committed to Asana's long-term success as Board Chair and I am excited to support Dan, especially with advancing our product vision and navigating the rapidly evolving AI landscape.' Under Moskovitz's leadership, Asana has grown into a leading enterprise work management platform for human and AI coordination. With more than 170,000 customers, Asana is trusted by over 85% of Fortune 500 companies and generates over $700 million in annual revenue. The company is recognized for its award-winning culture and innovative AI-powered solutions, which includes the recent launch of AI Studio. "On behalf of the Board, I want to thank Dustin for his visionary leadership and tireless dedication to Asana's mission,' said Lorrie Norrington, Asana's Lead Independent Director. 'We are thrilled to welcome Dan as our next CEO. His expertise and track record of leading innovative organizations makes him the ideal leader to embrace AI and drive Asana's continued growth and profitability." As CEO of LaunchDarkly, Rogers delivered on the vision of creating a platform for software teams to build successful products, expanding into release automation, experimentation, product analytics and AI engineering. As President of Rubrik, Rogers led products, marketing, specialist sales, go-to-market strategy, strategic alliances and corporate development. Prior to Rubrik, as Chief Marketing Officer at ServiceNow, Rogers was a part of the leadership team that grew the company to over $4.5 billion in revenue. Earlier in his career, Rogers held leadership roles at Amazon Web Services, Microsoft, Salesforce, and Symantec. Rogers graduated as a Baker Scholar from Harvard Business School and has a Bachelor of Science degree in economics from the University of Birmingham. Forward-Looking Statements This press release contains 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include, but are not limited to, statements about our forward growth and profitability, our market opportunity, the potential and impact of AI, our ability to execute on our current strategies, and our technology and brand position. Forward-looking statements generally relate to future events or Asana's future financial or operating performance. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'continue,' 'could,' 'potential,' 'may,' 'will,' 'goal,' or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including factors beyond Asana's control, that may cause Asana's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on risks, including but not limited to, risks and uncertainties related to the loss of one or more of Asana's key personnel, in particular Asana's co-founder, President, Chief Executive Officer, and Chair of the Board, Dustin Moskovitz, that could cause actual results to differ materially from forecasted results are included in Asana's filings with the SEC, including Asana's Quarterly Report on Form 10-Q for the quarter ended April 30, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release are based on assumptions that Asana believes to be reasonable as of this date. Except as required by law, Asana assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements. About Asana Asana is a leading work management platform for human and AI coordination. Over 170,000 customers like Accenture, Amazon, Anthropic, Morningstar, and Suzuki rely on Asana to align teams and accelerate organizational impact. Whether it's managing strategic initiatives, cross-functional programs, or company-wide goals, Asana helps organizations bring clarity to complexity—turning plans into action with AI working alongside teams every step of the way. To learn more, visit
